rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antinavikiniai vaistai - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
sildenafil accord
lex ano, uab - sildenafilis - plėvele dengta tabletė - 100 mg - sildenafil
abedel
elem magdalena pakulska - sildenafilis - plėvele dengtos tabletės - 50 mg - sildenafil
abedel
elem magdalena pakulska - sildenafilis - plėvele dengtos tabletės - 100 mg - sildenafil
tadilecto
lex ano, uab - tadalafilis - plėvele dengtos tabletės - 20 mg - tadalafil
sildenafil sandoz
lex ano, uab - sildenafilis - tabletės - 100 mg - sildenafil
alfacalcidol strides pharma
strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 0,25 µg - alfacalcidol
alfacalcidol strides pharma
strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 0,5 µg - alfacalcidol
alfacalcidol strides pharma
strides pharma (cyprus) limited - alfakalcidolis - minkštosios kapsulės - 1 µg - alfacalcidol
sildenafil g.l. pharma
g.l. pharma gmbh - sildenafilis - plėvele dengtos tabletės - 20 mg - sildenafil